Longboard Pharmaceuticals, Inc. (LBPH)
Longboard Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in La Jolla, CA, US. The stock last traded at $59.98, giving a market capitalisation of $2.34B. On trailing twelve-month figures it carries a trailing P/E of -25.10, a net margin of 0.0%. Its beta of 1.09 implies it has historically moved more than the broad market.
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company also boasts preclinical pipeline candidates, LP659 and LP143, designed to tackle a range of neurological diseases. Incorporated in 2020, the company, formerly known as Arena Neuroscience, Inc., adopted its current name, Longboard Pharmaceuticals, Inc., in October 2020. Its corporate headquarters are situated in La Jolla, California.
Longboard Pharmaceuticals, Inc. is most often compared with the following Healthcare names: